President Trump nominated White House domestic policy aide Dr. Heidi Overton on August 18-19, 2026, to serve as FDA commissioner following Marty Makary’s May resignation and acting commissioner Kyle Diamantas’s reported reluctance to accept the permanent role. Confirmation requires Senate approval, beginning with a vote in the Republican-led HELP Committee chaired by Sen. Bill Cassidy, who has already expressed strong reservations over Overton’s involvement in a recent executive order on childhood vaccines, describing it as potentially disqualifying. The narrow Republican Senate majority and committee scrutiny of her policy record on vaccines, mifepristone regulation, and agency priorities create near-term procedural hurdles, while scheduled hearings and any subsequent full-chamber vote will determine whether the nomination advances before the market resolution window closes.
Tóm tắt AI thử nghiệm tham chiếu dữ liệu Polymarket. Đây không phải tư vấn giao dịch và không ảnh hưởng đến cách thị trường này được giải quyết. · Cập nhậtMỚI
Sep 30, 2026
September 30
49%
October 31
66%
November 30
50%
December 31
73%
$1,166 KL.
September 30
$586 KL.
49%
October 31
$569 KL.
66%
November 30
$0 KL.
50%
December 31
$11 KL.
73%
This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by October 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by November 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.President Trump nominated White House domestic policy aide Dr. Heidi Overton on August 18-19, 2026, to serve as FDA commissioner following Marty Makary’s May resignation and acting commissioner Kyle Diamantas’s reported reluctance to accept the permanent role. Confirmation requires Senate approval, beginning with a vote in the Republican-led HELP Committee chaired by Sen. Bill Cassidy, who has already expressed strong reservations over Overton’s involvement in a recent executive order on childhood vaccines, describing it as potentially disqualifying. The narrow Republican Senate majority and committee scrutiny of her policy record on vaccines, mifepristone regulation, and agency priorities create near-term procedural hurdles, while scheduled hearings and any subsequent full-chamber vote will determine whether the nomination advances before the market resolution window closes.
This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.
Thị trường mở: Aug 20, 2026, 5:43 PM ET
Khối lượng
$1,166Ngày kết thúc
Jan 1, 2027Thị trường mở
Aug 20, 2026, 5:43 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by October 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by November 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.President Trump nominated White House domestic policy aide Dr. Heidi Overton on August 18-19, 2026, to serve as FDA commissioner following Marty Makary’s May resignation and acting commissioner Kyle Diamantas’s reported reluctance to accept the permanent role. Confirmation requires Senate approval, beginning with a vote in the Republican-led HELP Committee chaired by Sen. Bill Cassidy, who has already expressed strong reservations over Overton’s involvement in a recent executive order on childhood vaccines, describing it as potentially disqualifying. The narrow Republican Senate majority and committee scrutiny of her policy record on vaccines, mifepristone regulation, and agency priorities create near-term procedural hurdles, while scheduled hearings and any subsequent full-chamber vote will determine whether the nomination advances before the market resolution window closes.
This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.
Khối lượng
$1,166Ngày kết thúc
Jan 1, 2027Thị trường mở
Aug 20, 2026, 5:43 PM ETResolver
0x65070BE91...President Trump nominated White House domestic policy aide Dr. Heidi Overton on August 18-19, 2026, to serve as FDA commissioner following Marty Makary’s May resignation and acting commissioner Kyle Diamantas’s reported reluctance to accept the permanent role. Confirmation requires Senate approval, beginning with a vote in the Republican-led HELP Committee chaired by Sen. Bill Cassidy, who has already expressed strong reservations over Overton’s involvement in a recent executive order on childhood vaccines, describing it as potentially disqualifying. The narrow Republican Senate majority and committee scrutiny of her policy record on vaccines, mifepristone regulation, and agency priorities create near-term procedural hurdles, while scheduled hearings and any subsequent full-chamber vote will determine whether the nomination advances before the market resolution window closes.
Tóm tắt AI thử nghiệm tham chiếu dữ liệu Polymarket. Đây không phải tư vấn giao dịch và không ảnh hưởng đến cách thị trường này được giải quyết. · Cập nhật
Cẩn thận với liên kết bên ngoài.
Cẩn thận với liên kết bên ngoài.
Câu hỏi thường gặp